| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 216.87 mm | 216.87 mm | 216.87 mm | 216.87 mm | 216.87 mm | 216.87 mm |
| Cash burn (monthly) | (no burn) | 13.74 mm | 18.25 mm | 27.97 mm | 26.25 mm | 21.33 mm |
| Cash used (since last report) | n/a | 55.26 mm | 73.40 mm | 112.51 mm | 105.60 mm | 85.80 mm |
| Cash remaining | n/a | 161.61 mm | 143.47 mm | 104.36 mm | 111.27 mm | 131.07 mm |
| Runway (months of cash) | n/a | 11.8 | 7.9 | 3.7 | 4.2 | 6.1 |
| 13F holders | Current |
|---|---|
| Total holders | 125 |
| Opened positions | 23 |
| Closed positions | 13 |
| Increased positions | 43 |
| Reduced positions | 35 |
| 13F shares | Current |
|---|---|
| Total value | 376.30 bn |
| Total shares | 107.28 mm |
| Total puts | 17.60 k |
| Total calls | 25.80 k |
| Total put/call ratio | 0.7 |
| Largest owners | Shares | Value |
|---|---|---|
| T. Rowe Price Investment Management | 10.43 mm | $51.43 mm |
| Westlake BioPartners Fund II | 9.79 mm | $241.73 mm |
| AyurMaya Capital Management | 9.33 mm | $46.02 bn |
| Citadel Advisors | 6.52 mm | $32.16 bn |
| BlackRock | 5.98 mm | $29.49 bn |
| Millennium Management | 5.49 mm | $27.05 bn |
| Integrated Core Strategies | 5.15 mm | $24.65 mm |
| Ai Acel | 5.10 mm | $125.82 mm |
| Vanguard | 4.07 mm | $20.05 bn |
| Orbimed Advisors | 4.00 mm | $19.73 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 25 | Amar Murugan | Common Stock | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 125,500 |
| 23 Jan 25 | Mina Kim | Common Stock | Grant | Acquire A | No | No | 0 | 575,000 | 0.00 | 689,739 |
| 23 Jan 25 | Shephard Mpofu | Common Stock | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 125,000 |
| 25 Nov 24 | Amar Murugan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.73 | 525,000 | 2.48 mm | 525,000 |
